Global Beta-Adrenoceptor Agonists (β-agonists) Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Jan 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Beta-Adrenoceptor Agonists (β-agonists) Market, By Type (β1 Agonists, β2 Agonists, Others), Drugs (Epinephrine, Norepinephrine, Dopamine, Dobutamine, Isoproterenol, Others) Diseases (Asthma, Anaphylactic Shock, Cardiogenic Shock, Cardiac Arrest, Severe Hypotension, Septic Shock, Acute Heart Failure, Acute Renal Failure, Bradycardia and Atrioventricular Block Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Beta-Adrenoceptor Agonists (β-agonists) Market Market Analysis and Insights: Global Beta-Adrenoceptor Agonists (β-agonists) Market

Global beta-adrenoceptor agonists (β-agonists) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.00% in the above-mentioned research forecast period. Emerging markets and continuous rising prevalence of hypertension are the factors responsible for the growth of this market.

However, increasing company initiatives to provide better treatment and rising investment by biotechnology and pharmaceutical industries in R&D drive the global beta-adrenoceptor agonists (β-agonists) market. Moreover, technological advancement in treatment & diagnosis and favourable reimbursement policies also boost up the market growth. But, the presence of alternative treatment for hypertension may hamper the global beta-adrenoceptor agonists (β-agonists) market.

Beta-adrenoceptor agonists (β-agonists) bind to the β-receptors on the smooth muscle tissues and cardiac tissues. They also have important actions in other tissues, especially bronchial smooth muscle (relaxation), the liver (stimulate glycogenolysis), and kidneys (stimulate renin release). Beta-adrenoceptors normally bind to norepinephrine released by sympathetic adrenergic nerves, and to circulating epinephrine.

According to the WHO, it is estimated that 1.13 billion people worldwide have hypertension, most (two-thirds) living in low- and middle-income countries or 2015 it is estimated that in 1 in 4 men and 1 in 5 women had hypertension. 

This beta-adrenoceptor agonists (β-agonists) market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Beta-Adrenoceptor Agonists (β-agonists) Market Scope and Market Size

The beta-adrenoceptor agonists (β-agonists) market is segmented on the basis of type, drugs, diseases, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the beta-adrenoceptor agonists (β-agonists) market is segmented into β1 agonists, β2 agonists and others.
  • On the basis of drugs, the beta-adrenoceptor agonists (β-agonists) market is segmented into epinephrine, norepinephrine, dopamine, dobutamine, isoproterenol and others.
  • On the basis of diseases, the beta-adrenoceptor agonists (β-agonists) market is segmented into asthma, anaphylactic shock, cardiogenic shock, cardiac arrest, severe hypotension, septic shock, acute heart failure, acute renal failure, bradycardia & atrioventricular block and others.
  • On the basis of end-users, the beta-adrenoceptor agonists (β-agonists) market is segmented into hospitals, specialty clinics, home healthcare and others.
  • On the basis of distribution channel, the beta-adrenoceptor agonists (β-agonists) market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Beta-Adrenoceptor Agonists (β-agonists) Market Country Level Analysis

Beta-adrenoceptor agonists (β-agonists) market is analysed and market size information is provided by country, type, drugs, diseases, end-users and distribution channel as referenced above.

The countries covered in the beta-adrenoceptor agonists (β-agonists) market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the increased consumption of cardiovascular drugs for the treatment of cardiac diseases. Europe accounts the second largest market share due to increased obesity related diseases and presence of refined medical facilities. Asia Pacific region is the fastest growing region in the upcoming years due to rising healthcare infrastructure and rising government and pharmaceutical initiatives for the better treatment.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Beta-adrenoceptor agonists (β-agonists) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Beta-Adrenoceptor Agonists (β-agonists) Market Share Analysis

Beta-adrenoceptor agonists (β-agonists) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to beta-adrenoceptor agonists (β-agonists) market.

The major players covered in the beta-adrenoceptor agonists (β-agonists) market are FRESENIUS KABI USA, IMPAX, Par Pharmaceuticals, Hikma Pharmaceutical PLC, Mylan NV, Sun Pharmaceutical Industries Pvt. Ltd., Teva Pharmaceutical Industries Pvt. Ltd, Pfizer Inc, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd and Eisai Co., Ltd, Baxter, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available: Global Beta-Adrenoceptor Agonists (β-agonists) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions